Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976140 | 0.88 | CYP1A2 (0.32) | CYP1A2ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL977580 | 0.83 | CYP1A2 (0.32) | CYP1A2 | |
| SCHEMBL978235 | 0.81 | — | — | |
| SCHEMBL975974 | 0.81 | — | — | |
| SCHEMBL975975 | 0.81 | — | — | |
| SCHEMBL978563 | 0.80 | ADORA3 (0.32) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL975557 | 0.79 | KDM4E (0.31) | CYP1A2 | |
| SCHEMBL19349015 | 0.79 | CYP1A2 (0.30) | CYP1A2 | |
| SCHEMBL978593 | 0.78 | CYP1A2 (0.32) | CYP1A2 | |
| SCHEMBL978605 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2995619-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS COMPRISING IMIDAZOPYRIMIDINES | Cytokinetics, Inc. (US) | 2016-03-16 | — | — | EP | claimed |
| EP-2666777-A1 | Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods | Cytokinetics, Inc. (US) | 2013-11-27 | — | — | EP | claimed |
| EP-2583970-A1 | Certain chemical entities, compositions and methods comprising imidazopyrimidines | Cytokinetics, Inc. (US) | 2013-04-24 | — | — | EP | claimed |
| EP-2069352-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | claimed |
| WO-2008016669-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | claimed |
| CN-111840294-A | Method for improving resistance to skeletal muscle fatigue | 赛特凯恩蒂克公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYTOKINETICS, INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| EP-2995619-B1 | CERTAIN CHEMICAL ENTITIES COMPRISING IMIDAZOPYRIMIDINES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190167676-A1 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | CYTOKINETICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20170266192-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS INC (US) | 2017-09-21 | — | — | US | disclosed |
| EP-2069352-B9 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2995619-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS COMPRISING IMIDAZOPYRIMIDINES | Cytokinetics, Inc. (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2011-01-20 | — | — | US | disclosed |
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-04-15 | — | — | US | disclosed |
| US-7598248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-2069352-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008016669-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | CYP1A2 3794/4885ADORA3 3295/4885ADORA2A 4328/4885 |
| US-20170266192-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | TNNC1, TNNI3, DIAPH1 | CYP1A2 4687/4885ADORA3 3404/4885ADORA2A 2968/4885 |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | TNNC1, TNNI3, TNNT2 | CYP1A2 3794/4885ADORA3 3295/4885ADORA2A 4328/4885 |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYP4B1, CYP3A5, CYP4F12 | CYP1A2 20/4885ADORA3 3142/4885ADORA2A 1580/4885 |
| US-20190167676-A1 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | TNNC1, TNNI3, TNNT2 | CYP1A2 4298/4885ADORA3 3075/4885ADORA2A 2125/4885 |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNC1, TNNI3, TNNT2 | CYP1A2 3794/4885ADORA3 3295/4885ADORA2A 4328/4885 |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, TNNC1 | CYP1A2 3227/4885ADORA3 2376/4885ADORA2A 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.